Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.55 |
| ▸ | DHODH | Q02127 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8840168 | 0.91 | CYP19A1 (0.60) | TP53POLBALOX5TDP1SMN1; SMN2 | |
| SCHEMBL31548560 | 0.89 | CYP19A1 (0.58) | TP53POLBALOX5TDP1SMN1; SMN2 | |
| SCHEMBL17547789 | 0.87 | ALDH1A1 (0.58) | TP53POLBMAPK1ALOX5SMN1; SMN2 | |
| SCHEMBL3712556 | 0.85 | MAPT (0.50) | TP53ALOX5TDP1SMN1; SMN2CYP19A1 | |
| SCHEMBL1510458 | 0.85 | TP53 (0.50) | TP53POLBMAPK1ALOX5TDP1 | |
| SCHEMBL29727672 | 0.85 | TP53 (0.50) | TP53POLBMAPK1ALOX5TDP1 | |
| SCHEMBL18172435 | 0.85 | BCL2L1 (0.53) | TP53POLBMAPK1ALOX5TDP1 | |
| SCHEMBL18285305 | 0.85 | TP53 (0.50) | TP53POLBMAPK1ALOX5TDP1 | |
| SCHEMBL311273 | 0.85 | DHODH (0.51) | TP53POLBMAPK1DHODHTDP1 | |
| SCHEMBL29727642 | 0.85 | BCL2L1 (0.53) | TP53POLBMAPK1ALOX5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793996-A1 | KINASE INHIBITORS | The University of Manchester (GB) | 2021-03-24 | — | — | EP | disclosed |
| CN-112119077-A | Kinase inhibitors | 曼彻斯特大学 | 2020-12-22 | — | — | CN | disclosed |
| US-7981914-B2 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | AR, NAT1, TBXA2R | TP53 3030/4885POLB 3956/4885MAPK1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.